Titan Biotech shares jumped 4.86% to ₹435 following the company's board approval of a 1:4 bonus issue, subject to shareholder approval. As per Business Standard, the stock has delivered exceptional long-term performance with multibagger returns of 208% in the past one year and 536% over five years, positioning it as a strong performer in the biological products manufacturing sector. The board meeting scheduled for September 3, 2026, will consider and approve the maiden bonus issue proposal, with the company's share price up 4.86% to ₹435 as of 03:33 PM, while the Nifty 50 was trading 0.08% lower at 23,894.95.
The board has approved the 1:4 bonus issue where shareholders will receive one new fully paid-up equity share of ₹2 each for every four existing shares held on the record date, subject to shareholder approval and regulatory clearances. According to Business Standard, the bonus issue will increase the company's paid-up equity share capital from ₹8.26 crore to ₹10.33 crore. The company expects to credit or dispatch the bonus shares within two months of board approval, or by November 3, 2026, subject to necessary approvals. The bonus shares will be issued by utilising nearly ₹2.07 crore from the company's free reserves and share premium, with the company's balance of premium reserve and free reserves standing at ₹162.58 crore as on March 31, 2026.
The company's board of directors at its meeting held on May 30, 2026, recommended a final dividend of ₹0.50 per equity share of ₹2 each for the financial year 2025-26. As per Business Standard, the company has fixed Tuesday, September 22, 2026, as the record date for determining entitlement of members to the final dividend for the financial year ended March 31, 2026. The company will hold its 34th Annual General Meeting on September 29, 2026, with the board meeting also finalizing the time, date and venue for the AGM, approving the draft Notice of AGM and draft Director's Report for the year ended March 31, 2026, and finalizing dates for book closure, record date, and e-voting related matters.
On a consolidated basis, Titan Biotech's net profit rose 58.31% to ₹10.86 crore while net sales rose 27.25% to ₹59.17 crore in Q1 June 2026 over Q1 June 2025. As per Business Standard, the company is a manufacturers and exporters of biological products used in pharmaceutical, nutraceutical, food & beverages, biotechnology & fermentation, cosmetic, veterinary & animal feed, agriculture industries, microbiology culture media & plant tissue culture media. The strong quarterly performance demonstrates the company's robust operational efficiency and growth trajectory in the biological products sector.
From a technical perspective, Vipin Kumar, AVP research at Globe Capital Market, noted that the stock has been forming a higher-high and higher-low structure across multiple timeframes while holding firm above its key long-term and short-term moving averages. However, he cautioned that the volume and volume distribution are weak, leading to frequent price filters. Given this low liquidity, he advised traders to avoid the stock despite its technical strength. On the levels front, the ₹350–₹360 zone will act as an immediate strong support area, while resistance is positioned around the ₹500 level. The company continues to focus on manufacturing collagen, skincare, bone and joint care ingredients, proteins and animal nutrition products, maintaining its position in the biological products sector.
